Takeda Pharmaceutical Company Limited (TYO:4502)
Japan · Delayed Price · Currency is JPY 5,118.00
-2.00 (-0.04%)
May 29, 2026, 3:30 PM JST
TYO:4502 Income Statement
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 4,505,720 | 4,581,551 | 4,263,762 | 4,027,478 | 3,569,006 | |
Revenue Growth (YoY) | -1.65% | 7.45% | 5.87% | 12.85% | 11.61% |
Cost of Revenue | 1,571,588 | 1,571,419 | 1,431,505 | 1,253,163 | 1,127,308 |
Gross Profit | 2,934,132 | 3,010,132 | 2,832,257 | 2,774,315 | 2,441,698 |
Selling, General & Admin | 1,084,215 | 1,104,732 | 1,053,819 | 997,234 | 886,327 |
Research & Development | 675,924 | 730,226 | 728,617 | 633,325 | 526,087 |
Amortization of Goodwill & Intangibles | 504,244 | 548,186 | 521,525 | 485,102 | 418,789 |
Other Operating Expenses | 44,472 | 64,052 | 28,821 | 38,987 | 10,433 |
Operating Expenses | 2,308,855 | 2,447,196 | 2,332,782 | 2,154,648 | 1,841,636 |
Operating Income | 625,277 | 562,936 | 499,475 | 619,667 | 600,062 |
Interest Expense | -131,200 | -130,487 | -115,392 | -116,973 | -122,432 |
Interest & Investment Income | - | 19,983 | 11,628 | 5,781 | 4,763 |
Earnings From Equity Investments | -2,177 | -3,986 | 6,473 | -8,630 | -15,367 |
Currency Exchange Gain (Loss) | - | 786 | -13,612 | -9,729 | -3,903 |
Other Non Operating Income (Expenses) | -15,195 | -24,865 | -31,520 | 3,975 | -26,119 |
EBT Excluding Unusual Items | 476,705 | 424,367 | 357,052 | 494,091 | 437,004 |
Merger & Restructuring Charges | -70,800 | -128,133 | -81,358 | -59,234 | -83,836 |
Gain (Loss) on Sale of Investments | - | -18,885 | - | 22,416 | 8,482 |
Gain (Loss) on Sale of Assets | - | 10,561 | 7,975 | 8,901 | 8,164 |
Asset Writedown | -145,716 | -103,379 | -146,047 | -62,484 | -54,421 |
Legal Settlements | - | - | -45,212 | -16,455 | -20,319 |
Other Unusual Items | - | -9,447 | -39,619 | -12,145 | 7,497 |
Pretax Income | 260,189 | 175,084 | 52,791 | 375,090 | 302,571 |
Income Tax Expense | 68,163 | 66,941 | -91,406 | 58,052 | 72,405 |
Earnings From Continuing Operations | 192,026 | 108,143 | 144,197 | 317,038 | 230,166 |
Minority Interest in Earnings | -264 | -215 | -130 | -21 | -107 |
Net Income | 191,762 | 107,928 | 144,067 | 317,017 | 230,059 |
Net Income to Common | 191,762 | 107,928 | 144,067 | 317,017 | 230,059 |
Net Income Growth | 77.68% | -25.09% | -54.55% | 37.80% | -38.81% |
Shares Outstanding (Basic) | 1,575 | 1,579 | 1,564 | 1,552 | 1,564 |
Shares Outstanding (Diluted) | 1,603 | 1,605 | 1,580 | 1,570 | 1,577 |
Shares Change (YoY) | -0.16% | 1.58% | 0.67% | -0.46% | 0.23% |
EPS (Basic) | 121.75 | 68.36 | 92.09 | 204.29 | 147.14 |
EPS (Diluted) | 119.64 | 67.23 | 91.16 | 201.94 | 145.87 |
EPS Growth | 77.96% | -26.25% | -54.86% | 38.44% | -38.96% |
Free Cash Flow | 865,428 | 856,387 | 540,924 | 836,499 | 999,853 |
Free Cash Flow Per Share | 539.95 | 533.47 | 342.28 | 532.85 | 633.95 |
Dividend Per Share | 200.000 | 196.000 | 188.000 | 180.000 | 180.000 |
Dividend Growth | 2.04% | 4.25% | 4.44% | - | - |
Gross Margin | 65.12% | 65.70% | 66.43% | 68.88% | 68.41% |
Operating Margin | 13.88% | 12.29% | 11.71% | 15.39% | 16.81% |
Profit Margin | 4.26% | 2.36% | 3.38% | 7.87% | 6.45% |
Free Cash Flow Margin | 19.21% | 18.69% | 12.69% | 20.77% | 28.02% |
EBITDA | 1,346,404 | 1,233,262 | 1,143,936 | 1,284,067 | 1,183,213 |
EBITDA Margin | 29.88% | 26.92% | 26.83% | 31.88% | 33.15% |
D&A For EBITDA | 721,127 | 670,326 | 644,461 | 664,400 | 583,151 |
EBIT | 625,277 | 562,936 | 499,475 | 619,667 | 600,062 |
EBIT Margin | 13.88% | 12.29% | 11.71% | 15.39% | 16.81% |
Effective Tax Rate | 26.20% | 38.23% | - | 15.48% | 23.93% |